PMID: 6405844May 7, 1983Paper

Treatment of angina pectoris with nifedipine: importance of dose titration

British Medical Journal
J DeanfieldK M Fox

Abstract

The effects of different doses of nifedipine on frequency of angina and objective measurements of myocardial ischaemia during exercise were studied in 10 patients with stable angina pectoris. In a single blind trial over nine weeks patients received one week's treatment each with placebo, nifedipine 10 mg, 20 mg, 30 mg, 40 mg, 30 mg, 20 mg, 10 mg, then placebo three times a day. The response to the different doses of nifedipine was highly variable. On exercising, three patients achieved a consistent improvement in workload attained before onset of ST segment depression and maximum ST depression during exercise testing during all active phases. Four patients improved with 10 mg three times a day but deteriorated at higher doses. In two patients there was no objective or subjective improvement with any dose of the drug, while in one patient anginal frequency increased and there was objective deterioration during exercise testing at doses above 10 mg three times a day. Thus a dose of nifedipine that is beneficial in one patient may have minimal or opposite effects in another. These results indicate the importance of careful titration of doses for individual patients if the maximum benefit from nifedipine is to be obtained in patie...Continue Reading

References

Oct 22, 1979·The American Journal of Cardiology·S GoldbergJ A Kastor
May 6, 1978·British Medical Journal·A G Jariwalla, E G Anderson
Jun 17, 1978·British Medical Journal·C Rodger, A Stewart
Dec 9, 1978·British Medical Journal·K FoxJ Shillingford
Jul 1, 1981·British Heart Journal·H DargieD Krikler
Jul 1, 1981·Circulation·B FreedmanD T Kelly
Jan 1, 1980·Chemical & Pharmaceutical Bulletin·S KondoI Sugimoto

❮ Previous
Next ❯

Citations

May 1, 1988·Cardiovascular Drugs and Therapy·W Schulz
May 1, 1988·Cardiovascular Drugs and Therapy·D G Caralis, Z Kyriakides
Jan 1, 1991·European Journal of Clinical Pharmacology·B W KarlsonG Olsson
Jan 1, 1986·Rheumatology International·S J HawkinsP J Maddison
Jan 1, 1988·European Journal of Clinical Pharmacology·R L Logan
Jan 1, 1989·European Journal of Clinical Pharmacology·M KyriakidisP Toutouzas
Mar 3, 1984·Lancet·L H Opie
Oct 26, 1985·British Medical Journal·J Kenny
Oct 1, 1986·British Heart Journal·A A QuyyumiK M Fox
Jan 1, 1985·European Journal of Clinical Pharmacology·J P van MantgemA W Matroos
Aug 1, 1985·Mayo Clinic Proceedings·C ShubM D McGoon
Feb 1, 1990·Mayo Clinic Proceedings·C Shub
Mar 15, 1991·The American Journal of Cardiology·D TzivoniA Caspi
Jul 15, 1989·The American Journal of Cardiology·W ShapiroL R Zohman
Nov 1, 1989·British Journal of Clinical Pharmacology·V F ChallenorC F George
Nov 1, 1986·Journal of Clinical Pharmacology·L M GutierrezM Fisher
Jul 1, 1989·DICP : the Annals of Pharmacotherapy·M F Babich, M L Kalin
Jun 1, 1986·The Journal of Pharmacy and Pharmacology·L J LeskoG P Rodgers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.